Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P61088

UPID:
UBE2N_HUMAN

ALTERNATIVE NAMES:
Bendless-like ubiquitin-conjugating enzyme; E2 ubiquitin-conjugating enzyme N; Ubc13; UbcH13; Ubiquitin carrier protein N; Ubiquitin-protein ligase N

ALTERNATIVE UPACC:
P61088; Q16781; Q53Y81

BACKGROUND:
The Ubiquitin-conjugating enzyme E2 N, known as Ubc13, is integral to the error-free DNA repair pathway, contributing significantly to cell survival post-DNA damage. It collaborates with E3 ligases to mediate 'Lys-63'-linked polyubiquitination, a key process in inflammatory response, viral defense, and cell cycle control. Ubc13's action in conjunction with TRIM5 and RNF135 in viral RNA sensing and interferon beta production highlights its role in innate immunity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Ubiquitin-conjugating enzyme E2 N unveils promising avenues for developing novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.